The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
I share the same concern regarding PQ but now I think it was done to support P
placing. If PQ run 3 fails they will have to redo all 3. The fact that 1 & 2 successfully completed makes it unlikely. On the off chance there was an issue, then should have no issue successfully completing 3 more. At worst a small delay.
He wasn't the only one who knew. Some very active commentators noticeably absent the last few weeks. My guess, they got the opportunity to partake. I had my own suspicion but wasn't in a position to sell and rebuy.
Big pharma won't give 2 hoots about your cash balance if they wat your product. While pharma 'A' are trying to leverage your poor cash position, pharma 'b' swoops in and pays full value. If pharma want it they will pay.
Still not fully funded. Surely if PQ is delared a sucess and IND lodged which one could assume couldn't have been far away surely placing could have been done higher. I suspected last RNS was early and before confirmation, knoe why now. Some notable commentators very quiet the last while. Looks like sunny wasn't the only one that knew.
The results are known since Oct 2020.
Maybe waiting for Steve to be done or at least reach a much lower level?
Maybe their waiting for Steve to be done so they can release news and not have him sell into it.
If I'm in the US accumulating why should I care about the 3% rule????
I could go on every pre-clinical pharma and AIM Share's message board and shout placing incoming, eventually I would be right on almost all of them. Wouldn't consider myself to be calling it right though. (Yes, I know HEMO is not on AIM)